Liposomal Formulation of the CDK9 PROTAC THAL-SNS-032 Enhances the Antitumor activity in Breast Cancer

Liposomal Formulation of the CDK9 PROTAC THAL-SNS-032 Enhances the Antitumor activity in Breast Cancer

Jul 15, 2025 | Artificial Intelligence, PROTACs, Publications, SCIENCE

biospain_cancerappy

Thrilled to announce our latest work in Biomedicine & Pharmacotherapy (July 12, 2025): “Liposomal formulation of the CDK9 PROTAC THAL‑SNS‑032 enhances the antitumor activity in breast cancer cell lines.”

In this study, we tackled a key hurdle in PROTAC therapeutics—bioavailability and off‑target toxicity—by converting THAL‑SNS‑032, a potent CDK9‑targeting PROTAC, into three lipid‑based nano‑formulations: solid lipid nanoparticles (SLN‑THAL), cholesterol‑free liposomes (LIP‑THAL), and cholesterol‑loaded liposomes (cLIP‑THAL). Of these, cLIP‑THAL stood out for stability, controlled release, and impressive in vitro efficacy against breast cancer cell lines. Importantly, it maintained anticancer potency comparable to free PROTACs while showing reduced toxicity in non‑cancerous cells.

By encapsulating THAL‑SNS‑032 in nanocarriers, we improved pharmacological properties and safety, paving the way for next‑gen nanomedicine applications of PROTACs in oncology. This could mark a significant step toward targeted, safer therapies for breast cancer

Integrating artificial intelligence in drug discovery and early drug development

Integrating artificial intelligence in drug discovery and early drug development

Apr 8, 2025 | Artificial Intelligence, Cancer Reseach, Publications

biospain_cancerappy

Cancerappy Participates in New Scientific Publication on AI in Drug Discovery

We’re proud to announce that Cancerappy has contributed to a recently published paper in Biomarker Research titled “Artificial intelligence in drug discovery and early development: current landscape and future opportunities”.

This publication explores how artificial intelligence is reshaping the drug development landscape—from identifying new therapeutic targets to optimizing clinical trial design. It highlights real-world applications and discusses the potential of AI to accelerate innovation, reduce development costs, and bring new therapies to patients faster and more efficiently.

At Cancerappy, we strongly believe in the value of AI to transform oncology drug discovery. Our involvement in this work reflects our commitment to advancing research and supporting the integration of cutting-edge technologies in cancer therapeutics.

Cancerappy: Using AI to Advance Cancer Research

Cancerappy: Using AI to Advance Cancer Research

Nov 4, 2024 | Artificial Intelligence, Big Data, Cancer Reseach

Since 2019, Cancerappy has been harnessing the power of artificial intelligence to transform cancer research, from improving detection and diagnosis to developing more effective treatments with fewer side effects. We’re putting AI to work in areas like genomics, protein structure prediction, and drug discovery.

Here’s how AI drives our programs:

  • New Drug Development: AI speeds up drug discovery, making it faster, more cost-effective, and precise. It helps us screen drugs, predict multi-target effects, and find new uses for existing drugs.

  • Identifying Targets: AI enables us to design proteins and identify new therapeutic targets, opening doors to innovative treatments.

  • Handling Big Data: Cancer research generates huge data sets. AI helps us spot patterns, clean up data, and draw accurate conclusions.

  • Linking Data for Deeper Insights: By connecting data from diverse technologies, AI gives us a richer perspective and opens new research pathways.

At Cancerappy, AI is more than a tool—it’s a game-changer in our mission to make cancer treatments more effective and targeted.